iResearch Atlanta

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Depression4 trials
• Alzheimer disease2 trials
• Fatty liver disease (MASLD/MASH)1 trial
• Obesity1 trial
• Parkinson disease1 trial

Phase

• Phase 33 trials
• Phase 12 trials
• Phase 1/21 trial
• Phase 21 trial
• Phase 2/31 trial

Status

• Completed5 trials
• Active, not recruiting2 trials
• Recruiting1 trial

Lead sponsor

• Boehringer Ingelheim3 trials
• Eli Lilly and Company2 trials
• Annovis Bio Inc.1 trial
• COMPASS Pathways1 trial
• Cybin IRL Limited1 trial

Running trials

• Recruiting

  A Study of Buntanetap in Participants With PD

  NCT07284784· Phase 2/3· Annovis Bio Inc.· Source

  Contact: Elizabeth Davis

• Active, not recruiting

  Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

  NCT05711940· Phase 3· COMPASS Pathways· Source

• Active, not recruiting

  A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

  NCT05026866· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Parkinson disease1 recruiting

Closed trials

• Completed

  A Study to Test Different Doses of BI 1569912 in People With Depression

  NCT06558344· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease

  NCT05970640· Phase 1· Boehringer Ingelheim· Source

• Completed

  A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder

  NCT05385783· Phase 1/2· Cybin IRL Limited· Source

• Completed

  A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

  NCT05463731· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication

  NCT04937829· Phase 1· Boehringer Ingelheim· Source